UCB
- Revenue€5.5 BFY, 2021
- Market Capitalization€16.6 B2022-05-13
OverviewSuggest Edit
UCB is a biopharma company, focusing on neurology and immunology. It develops products for the treatment of epilepsy, Parkinson's disease, restless legs syndrome, ankylosing spondylitis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis.
| Type | Public | |
| Founded | 1928 | |
| HQ | Anderlecht, BE | Map |
| Website | ucb.com | |
| Employee Ratings | ||
| Overall Culture | D | More |
Recent NewsAll News
- UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting
- UCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022
- BrightInsight and UCB Partner to Build Digital Care Solutions for Rare Diseases
- UCB to buy U.S. biopharmaceutical Zogenix in $1.9 billion deal
Key People/Management at UCB
Jean-Christophe Tellier
Chief Executive Officer & Chairman of the Executive Committee
Kirsten Lund-Jurgensen
Executive Vice President of Supply & Technology Solutions
Dhavalkumar Patel
Executive Vice President &
Chief Scientific Officer
Emmanuel Caeymaex
Executive Vice President of Immunology Solutions & Head of US
Jean-Luc Fleurial
Executive Vice President & Chief Human Resources Officer
Iris Low-Friedrich
Executive Vice President & Chief Medical Officer
UCB Office Locations
UCB has offices in Anderlecht, Braine-l'Alleud, Raleigh, Smyrna and in 36 other locations
Anderlecht, BE (HQ)
60 Allée de la Recherche
Braine-l'Alleud, BE
Chemin du Foriest
Malvern, AU
Level 1/1155 Malvern Rd
Wien, AT
Twin Tower Wienerbergstrasse 11/12a
São Paulo, BR
Av. Presidente Juscelino Kubitschek, n° 1.327, 5° andar,
Condominio Edificio Intemacional Plaza II
Sofia, BG
2B Srebarna street, fl. 9, office 8B
UCB Financials and Metrics
UCB Revenue
UCB's revenue was reported to be €5.47 b in FY, 2021
| EUR | |
|---|---|
Revenue (FY, 2021) | 5.5b |
Gross profit (FY, 2021) | 4.8b |
Net income (FY, 2021) | 1.1b |
EBITDA (FY, 2021) | 1.6b |
EBIT (FY, 2021) | 1.3b |
Market capitalization (13-May-2022) | 16.6b |
Closing stock price (13-May-2022) | 88.0 |
Cash (31-Dec-2021) | 1.3b |
EV | 17.5b |
UCB's current market capitalization is €16.6 b.
Annual
| EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Revenue | 4.4b | 4.7b | 5.1b | 5.5b |
Cost of goods sold | (911.0m) | (955.0m) | (1.0b) | (1.1b) |
Gross profit | 3.8b | 4.0b | 4.5b | 4.8b |
R&D expense | (1.2b) | (1.3b) | (1.6b) | (1.6b) |
Half Year
| EUR | H1, 2019 | H1, 2020 | H1, 2021 |
|---|---|---|---|
Revenue | 2.2b | 2.5b | 2.7b |
Cost of goods sold | (446.0m) | (511.0m) | (526.0m) |
Gross profit | 1.9b | 2.1b | 2.3b |
R&D expense | (568.0m) | (689.0m) | (753.0m) |
Annual
| EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Cash | 1.3b | 1.3b | 1.3b | 1.3b |
Accounts Receivable | 616.0m | 686.0m | 742.0m | 887.0m |
Prepaid Expenses | 219.0m | 228.0m | 226.0m | 249.0m |
Inventories | 647.0m | 780.0m | 854.0m | 878.0m |
Half Year
| EUR | H1, 2019 | H1, 2020 | H1, 2021 |
|---|---|---|---|
Cash | 1.0b | 968.0m | 568.0m |
Accounts Receivable | 940.0m | 1.1b | 1.2b |
Prepaid Expenses | 50.0m | 31.0m | 65.0m |
Inventories | 706.0m | 825.0m | 894.0m |
Annual
| EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Net Income | 800.0m | 792.0m | 732.0m | 1.1b |
Depreciation and Amortization | 288.0m | 313.0m | 354.0m | 283.0m |
Inventories | (53.0m) | (134.0m) | (74.0m) | (24.0m) |
Accounts Payable | 69.0m | 60.0m | 258.0m |
Half Year
| EUR | H1, 2019 | H1, 2020 | H1, 2021 |
|---|---|---|---|
Net Income | 411.0m | 363.0m | 571.0m |
Depreciation and Amortization | 152.0m | 172.0m | 168.0m |
Inventories | (59.0m) | (45.0m) | (40.0m) |
Accounts Payable | (69.0m) | 106.0m | (56.0m) |
| EUR | FY, 2018 |
|---|---|
Revenue/Employee | 632.7k |
UCB Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Ra Pharmaceuticals | April 02, 2020 | $2.3 b |
| Alden Health, Inc. | ||
| Beryllium Discovery Corp. | ||
| Celltech Group Ltd | ||
| Celltech R&D Ltd | ||
| Darwin Discovery Ltd | ||
| Doutors Réassurance SA | ||
| Edev Sàrl | ||
| Element Genomics Inc. | ||
| Engage Therapeutics, Inc. |
UCB Revenue Breakdown
UCB revenue breakdown by business segment: 94.7% from NET SALES and 5.3% from Other
UCB Cybersecurity Score
UCB Environment, Social & Governance (ESG) Ratings
UCB Online and Social Media Presence
10.79k Twitter followers
UCB has 10.79k Twitter Followers. The number of followers has increased 0.6% month over month and increased 1.3% quarter over quarter
UCB's Trends
Twitter Engagement Stats for @ucb_news
2.7k
Tweets
1.9k
Following
10.8k
Followers
30
Tweets last 30 days
4.4
Avg. likes per Tweet
96.7%
Tweets with engagement
UCB Company Culture
Overall Culture
D
59/100
CEO Rating
F
33/100
Compensation
A+
100/100
UCB News and Updates
April 01, 2022
UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting
Scientific presentations illustrate UCB's commitment to addressing unmet needs of people living with a broad range of serious neurological diseases New data focused on epilepsy and Parkinson's disease (PD), including real-world use of BRIVIACT® (brivaracetam) CV, long-term use of...
March 25, 2022
UCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022
*** Unofficial English translation – For convenience purposes only ***
March 08, 2022
BrightInsight and UCB Partner to Build Digital Care Solutions for Rare Diseases
UCB’s Digital Care Solutions for Myasthenia Gravis to be Built on the BrightInsight Platform UCB’s Digital Care Solutions for Myasthenia Gravis to be Built on the BrightInsight Platform
January 19, 2022
UCB to buy U.S. biopharmaceutical Zogenix in $1.9 billion deal
UCB to buy U.S. biopharmaceutical Zogenix in $1.9 billion deal
January 19, 2022
UCB to Buy Epilepsy Drugmaker Zogenix for Up to $1.9 Billion
UCB to Buy Seizure Drugmaker Zogenix for Up to $1.9 Billion
December 10, 2021
UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis
BRUSSELS, Dec. 10, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline results from the Phase 3 MycarinG study1 evaluating rozanolixizumab, a subcutaneously (SC) infused monoclonal antibody targeting the neonatal Fc receptor (FcRn), versus...
UCB Blogs
February 04, 2022
UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
Migration
Fri 04/02/2022 - 06:00
UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
Positive…
February 02, 2022
Transparency notification FMR LLC.
Transparency notification FMR LLC.
Migration
Wed 02/02/2022 - 19:00
Transparency notification FMR LLC.
Notification referring to situation on 27 January 2022
Threshold crossed: 5%
Latest holding: 4.98%
…
February 02, 2022
UCB Receives Positive CHMP Opinion Recommending Approval of BRIVIACT[®] (brivaracetam) and VIMPAT[®] (lacosamide) in the EU for Partial-Onset Seizures in Pediatric Patients From Two to Four Years
UCB Receives Positive CHMP Opinion Recommending Approval of BRIVIACT[®] (brivaracetam) and VIMPAT[®] (lacosamide) in the EU for Partial-Onset Seizures in Pediatric Patients From Two to Four Years
Migration
Wed 02/02/2022 - 06:00
UCB Receives Positive CHMP Opin…
February 01, 2022
UCB Commences Tender Offer to Acquire Zogenix, Inc.
UCB Commences Tender Offer to Acquire Zogenix, Inc.
Migration
Tue 01/02/2022 - 17:00
UCB Commences Tender Offer to Acquire Zogenix, Inc.
Brussels (Belgium) 1 February 2022, 18:00 CET – UCB (Euronext: UCB) is commenci…
January 24, 2022
BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma
BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma
Migration
Mon 24/01/2022 - 06:00
BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Gener…
January 21, 2022
Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study
Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study
Migration
Fri 21/01/2022 - 06:00
Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study
…
UCB Frequently Asked Questions
When was UCB founded?
UCB was founded in 1928.
Who are UCB key executives?
UCB's key executives are Jean-Christophe Tellier, Kirsten Lund-Jurgensen and Dhavalkumar Patel.
How many employees does UCB have?
UCB has 7,600 employees.
What is UCB revenue?
Latest UCB annual revenue is €5.5 b.
What is UCB revenue per employee?
Latest UCB revenue per employee is €719.9 k.
Who are UCB competitors?
Competitors of UCB include Jazz Pharmaceuticals, Lundbeck and Amarin.
Where is UCB headquarters?
UCB headquarters is located at 60 Allée de la Recherche, Anderlecht.
Where are UCB offices?
UCB has offices in Anderlecht, Braine-l'Alleud, Raleigh, Smyrna and in 36 other locations.
How many offices does UCB have?
UCB has 40 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies